AMLX vs VLTO · $561.6M cap vs P/E 29, rev $5.50B
Amylyx Pharmaceuticals Inc (AMLX) versus Veralto Corporation (VLTO) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Veralto Corporation (VLTO) is a pollution & treatment controls company listed on US.
Latest reported AMLX revenue for 2025-12-31 was $0. Net income was -$144.7M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AMLX currently screens at market cap $561.6M.
Latest reported VLTO revenue for 2025-12-31 was $5.50B. Net income was $940.0M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
AMLX currently screens at market cap $561.6M. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
Not investment advice. Open the AMLX and VLTO stock pages for the full models.
Not investment advice.